UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 16, 2016

OCULUS INNOVATIVE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

001-33216 **Delaware** 68-0423298 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 1129 N. McDowell Blvd, Petaluma, CA 94954 (Address of principal executive offices) (Zip Code) (707) 283-0550 (Registrant's telephone number, including area code) Not applicable. (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

As previously reported, our adjourned meeting of stockholders was held on September 16, 2016. Stockholders voted on Proposal 4. Proxies were solicited pursuant to our definitive proxy statement filed on July 29, 2016 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934.

The number of shares of the Company's common stock entitled to vote at the annual meeting was 4,200,756. The number of shares of common stock present or represented by valid proxy at the annual meeting was 2,989,603, of which 2,455,235 were broker non-votes. Each share of common stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the annual meeting. At the annual meeting, our stockholders voted on the matters set forth below.

Proposal 4 – Vote to Approve Our 2016 Equity Incentive Plan

Our stockholders voted upon and approved our 2016 Equity Incentive Plan. The votes on this proposal were as follows:

FOR	AGAINST	ABSTAIN
274,551	230,479	42,139

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 19, 2016 OCULUS INNOVATIVE SCIENCES, INC.

By: <u>/s/ Robert Miller</u> Name: Robert Miller

Title: Chief Financial Officer